MediciNova wraps enrollment for interstitial cystitis trial of MN-001

By Angela McDaniels

Seattle, Sept. 5 - MediciNova, Inc. successfully completed enrollment in its phase 2/3 pivotal clinical trial of MN-001 in patients with moderate-to-severe interstitial cystitis, according to a company news release.

The randomized, double-blind, placebo-controlled study is being conducted at 34 sites in the United States and will include 305 patients. The primary endpoint of the study is the percentage of patients whose condition is at least "moderately improved" for each treatment group.

The San Diego-based specialty pharmaceutical company plans to have trial results by the end of the year.

Interstitial cystitis is a chronic disease of the bladder characterized by urinary frequency, urgency, night-time urination and pelvic and bladder pain. MN-001 is a novel, orally bioavailable compound that has been shown to block a number of the inflammatory mechanisms involved in interstitial cystitis and asthma, according to the release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.